Adverum Biotechnologies Inc
Prices are adjusted according to historical splits.
- Today's Low:
- Today's High:
- Open Price:
- 52W Low:
- 52W High:
- Prev. Close:
- Market Cap.:
- $81.56 million
- Book Value:
- Revenue TTM:
- Operating Margin TTM:
- Gross Profit TTM:
- Profit Margin:
- Return on Assets TTM:
- Return on Equity TTM:
Adverum Biotechnologies Inc had its IPO on 2014-07-31 under the ticker symbol ADVM.
The company operates in the Healthcare sector and Biotechnology industry. Adverum Biotechnologies Inc has a staff strength of 188 employees.
Shares of Adverum Biotechnologies Inc opened at $0.85 at the start of the last trading session i.e. 2023-03-19.
The stocks traded within a range of $0.75 - $0.86, and closed at $0.75.
This is a -11.44% slip from the previous day's closing price.
A total volume of 811,500 shares were traded at the close of the day’s session.
In the last one week, shares of Adverum Biotechnologies Inc have slipped by -7.28%.
Adverum Biotechnologies Inc's Key Ratios
Adverum Biotechnologies Inc has a market cap of $81.56 million, indicating a price to book ratio of 0.3022 and a price to sales ratio of 3419.8542.
In the last 12-months Adverum Biotechnologies Inc’s revenue was $0 with a gross profit of $-81681000 and an EBITDA of $-144788992. The EBITDA ratio measures Adverum Biotechnologies Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Adverum Biotechnologies Inc’s operating margin was 0% while its return on assets stood at -22.93% with a return of equity of -56.36%.
In Q3, Adverum Biotechnologies Inc’s quarterly earnings growth was a positive 0% while revenue growth was a negative 70%.
Adverum Biotechnologies Inc’s PE and PEG Ratio
- Forward PE
- Trailing PE
Its diluted EPS in the last 12-months stands at $-1.68 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Adverum Biotechnologies Inc’s profitability.
Adverum Biotechnologies Inc stock is trading at a EV to sales ratio of 3700.6388 and a EV to EBITDA ratio of 0.2285. Its price to sales ratio in the trailing 12-months stood at 3419.8542.
Adverum Biotechnologies Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $332.36 million
- Total Liabilities
- $28.62 million
- Operating Cash Flow
- $24.37 million
- Capital Expenditure
- Dividend Payout Ratio
Adverum Biotechnologies Inc ended 2023 with $332.36 million in total assets and $0 in total liabilities. Its intangible assets were valued at $332.36 million while shareholder equity stood at $208.34 million.
Adverum Biotechnologies Inc ended 2023 with $0 in deferred long-term liabilities, $28.62 million in other current liabilities, 10000.00 in common stock, $-769876000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $84.43 million and cash and short-term investments were $203.26 million. The company’s total short-term debt was $11,236,000 while long-term debt stood at $0.
Adverum Biotechnologies Inc’s total current assets stands at $213.24 million while long-term investments were $0 and short-term investments were $118.83 million. Its net receivables were $155000.00 compared to accounts payable of $846000.00 and inventory worth $0.
In 2023, Adverum Biotechnologies Inc's operating cash flow was $24.37 million while its capital expenditure stood at $824000.
Comparatively, Adverum Biotechnologies Inc paid $0 in dividends in 2023.
Other key metrics
- Current Trading Price
- 52-Week High
- 52-Week Low
- Analyst Target Price
Adverum Biotechnologies Inc stock is currently trading at $0.75 per share. It touched a 52-week high of $1.82 and a 52-week low of $1.82. Analysts tracking the stock have a 12-month average target price of $3.67.
Its 50-day moving average was $0.7 and 200-day moving average was $0.95 The short ratio stood at 4.15 indicating a short percent outstanding of 0%.
Around 367.9% of the company’s stock are held by insiders while 5839.7% are held by institutions.
Frequently Asked Questions About Adverum Biotechnologies Inc
Similar Industry Stocks (Biotechnology)
Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration and diabetic macular edema. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; Cornell University; GenSight; Lexeo; and Virovek. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.